Abbreviations: ACT = activated clotting time; aPTT = activated partial thromboplastin time; HIT = heparin-induced thrombocytopenia; TFPI = tissue factor pathway inhibitor; FDP = fibrin degradation products * Antithrombin III is now commonly referred to as antithrombin 
LOW-MOLECULAR-WEIGHT HEPARINS
Low-molecular-weight (LMW) heparins are fragments of commercial grade heparin with potent antithrombotic properties. LMW heparins have numerous features distinct from unfractionated heparin (UFH), including a more predictable anticoagulation effect, lack of inhibition by platelet factor-4, lack of need for monitoring, and a lower risk of HIT ( ). Local delivery of enoxaparin showed a reduction in angiographic restenosis after stenting (POLONIA 70 trial), but other trials showed no difference in restenosis or late MACE between LMW heparin and UFH. LMW heparin has also been evaluated for extended therapy in high-risk post-stent patients: In ATLAST, 68 overall event rates were low, and there was no incremental benefit for enoxaparin compared to standard antiplatelet therapy. In fact, bleeding complications were more frequent after enoxaparin. More recently, observational studies of enoxaparin with (NICE-4) 71 and without (NICE-1)i 72 platelet glycoprotein IIb/IIIa receptor antagonists for routine procedural anticoagulation have been completed. These studies and others 73 suggest that enoxaparin is safe and effective, and may be a reasonable alternative to UFH for procedural anticoagulation in the interventional setting. The recently completed NICE-3 study 74 demonstrated that patients with acute coronary syndromes receiving a IIb/IIIa antagonist and subcutaneous enoxaparin could safely undergo percutaneous revascularization without UFH. In ACUTE II, 75 a randomized trial of enoxaparin vs. UFH in interventional patients receiving tirofiban, safety and efficacy endpoints were similar between groups. Future data from INTERACT and CRUISE will help clarify the role of LMW heparin and IIb/IIIa antagonists in the cath lab. For now, LMW heparins are reasonable alternatives to UFH for procedural anticoagulation, but are not superior to UFH during percutaneous intervention in terms of reducing ischemic complications. Summary: Compared to unfractionated heparin, LMW heparins have distinct advantages, including ease of administration and lack of need for intensive monitoring (primarily due to less protein binding). However, in patients undergoing percutaneous intervention, LMW heparins have not yet been shown to be superior to unfractionated heparin; cost is a clear disadvantage of LMW heparins. Further studies as adjuncts to platelet IIb/IIIa inhibitors are in progress.
Abbreviations: ACS = acute coronary syndrome; MACE = major adverse cardiac events; PCI = percutaneous coronary intervention; UFH = unfractionated heparin Acronyms: See Table 34 .31, p. 803
DIRECT THROMBIN INHIBITORS
Direct thrombin inhibitors are generally classified as polypeptide or low-molecular weight inhibitors 76 (Table 34 .10). Polypeptide inhibitors such as hirudin (recombinant hirudin is lepirudin) and bivalirudin (hirulog) inactivate circulating thrombin via the active binding site and clot-bound thrombin via exosite-1. Low-molecular weight inhibitors such as argatroban also inactivate circulating thrombin via the active binding site, but do not inactivate clot-bound thrombin. Unlike heparin, direct thrombin inhibitors such as hirudin and bivalirudin do not require antithrombin for anticoagulant effect, form highly stable noncovalent complexes with circulating and clot-bound thrombin, and are not inhibited by platelet factor 4 (Tables 34.11, 34.12) . Although a pilot study reported that bivalirudin was similar to heparin in decreasing ischemic complications after PTCA, 77 a subsequent study reported fewer ischemic and bleeding complications with bivalirudin in high-risk patients with post-infarction angina. 78 In the Hirudin European Trial versus Heparin in the Prevention of Restenosis after PTCA (HELVETICA), 79 PTCA patients with unstable angina had fewer early ischemic events after hirudin, but no difference in restenosis. A higher incidence of intracranial hemorrhage has been reported in three trials combining hirudin and thrombolytic therapy (GUSTO IIa, 80 TIMI 9A, 81 HIT-III 82 ). The ongoing CACHET and REPLACE trials are evaluating the efficacy of bivalirudin (with "rescue" IIb/IIIa antagonist if necessary) vs. unfractionated heparin with routine IIb/IIIa antagonist during coronary intervention (Table 34 .13). In the United States, lepirudin (Refludan, a recombinant hirudin) and argatroban (Acova, a small molecule active site inhibitor) are approved for use in patients with heparin-induced thrombocytopenia who require IV anticoagulation. In such patients, lepirudin is administered as an initial bolus of 0.4 mg/kg (maximum 44 mg) over 15-20 seconds, followed by a continuous infusion of 0.15 mg/kg/hr (maximum rate 16.5 mg/hr). Monitoring is accomplished using the same aPTT guidelines as for UFH. Bivalirudin (Angiomax) has recently been approved for procedural anticoagulation in unstable angina. Abbreviations: FDP = fibrin degradation products; PF-4 = platelet factor-4 * Hirudin, bivalirudin 
